News und Analysen
Dexcom richtet den Blick auf die Zukunft der kontinuierlichen Blutzuckermessung
DexCom, Inc. (Nasdaq: DXCM), der Weltmarktführer im Bereich der kontinuierlichen Blutzuckermessung in Echtzeit für Menschen mit Diabetes, hat heute während der 14. Internationalen Konferenz über
Deciphera Pharmaceuticals Presents Data from QINLOCK® and Rebastinib Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced two e-poster
Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT Trial at the 2021 ASCO Annual Meeting
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented interim results from the Phase II SUMMIT basket trial, assessing the efficacy of neratinib in patients with EGFR exon
Puma Biotechnology Presents Data from the Phase III ExteNET Trial in Early Stage HER2-Positive Breast Cancer Patients at the Virtual 2021 ASCO Annual Meeting
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented results from the Phase III ExteNET trial assessing the impact of neratinib treatment duration on overall survival
Puma Biotechnology Presents Data Comparing Findings from the Phase II CONTROL Trial with the Neratinib Arm of the Phase III ExteNET Trial at the ASCO 2021 Annual Meeting
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, presented results at the virtual 2021 ASCO Annual Meeting comparing the diarrhea mitigation strategies investigated in the
Cell-Free DNA Guided Targeted Therapy Leads to Better Survival in Advanced Non-Small Cell Lung Cancer
Agilent Technologies Inc. (NYSE: A) today announced a presentation by Memorial Sloan Kettering Cancer Center (MSK) at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO)
Valbiotis meldet Veröffentlichung der ersten wissenschaftlichen Beiträge zu TOTUM•63 in drei internationalen Fachzeitschriften — Darlegung des an mehreren Stellen ansetzenden Wirkmechanismus
Valbiotis (FR0013254851 – ALVAL, PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
Valbiotis Announces the Publication of the First Scientific Papers on TOTUM•63 in Three International Journals, Elucidating Its Multitarget Mode of Action
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases
Dexcom Looks to the Future of Continuous Glucose Monitoring
DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the publication and presentation of two new studies during the 14
PQA Presents CarePlus Health Plans with its Excellence in Quality Award
CarePlus Health Plans, Inc., Florida’s largest* 5 out of 5-star Medicare Advantage plan, has been recognized by the Pharmacy Quality Alliance (PQA) with its Excellence in Quality award for
LivaNova vollzieht den initialen Verkaufsabschluss des Herzklappengeschäfts an Gyrus Capital
LivaNova PLC (NASDAQ:LIVN), ein marktführendes Unternehmen im Bereich Medizintechnik und Innovation, gab heute bekannt, dass es den initialen Abschluss der Veräußerung seines Herzklappengeschäfts
Agilent Announces New SureSelect Human All Exon V8
Agilent Technologies Inc. (NYSE: A) today announced the release of SureSelect Human All Exon V8 – a new exome design that provides comprehensive content and up-to-date coverage of protein coding
NANOBIOTIX Announces the Appointment of Bart Van Rhijn as Chief Financial Officer and Member of the Executive Board to Support Global Expansion
Regulatory News:
NANOBIOTIX (Euronext : NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
CenterWell Senior Primary Care Extends its Value-Based Care to People with Original Medicare
CenterWell Senior Primary Care, a fast-growing provider of whole-person, senior-focused healthcare, is participating in a new federal population health program that will allow CenterWell to extend
Hanger to Present at the Jefferies Virtual Healthcare Conference
Hanger, Inc. (NYSE: HNGR), a leading provider of orthotic and prosthetic patient care services and solutions, announced today that members of its management team will participate in presentations
Agilent Presents Thought Leader Award to Professor Chris Elliott
Agilent Technologies Inc. (NYSE: A) today announced that Chris Elliott has received an Agilent Thought Leader Award. Dr. Elliott is Professor of Food Safety in the School of Biological Sciences and
LivaNova Completes Initial Closing of Heart Valve Business to Gyrus Capital
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it has successfully completed the initial closing of the divestiture of its heart valve (HV)
Illumina Supports Nationwide Program across Belgium to Assess Whole Genome Sequencing for Developmental Disorders Diagnosis
Today, Illumina, Inc. (NASDAQ:ILMN) announced an agreement with the Belgian Genetic Centers to evaluate whole-genome sequencing (WGS) for the diagnosis of patients with intellectual disabilities
GenSight Biologics Announces Publication of Indirect Comparison Showing Treatment Effect of LUMEVOQ® versus Natural History in Frontiers in Neurology
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
Illumina and Next Generation Genomic Partner to Launch VeriSeq™ NIPT Solution in Thailand
Illumina, Inc., the global leader in DNA sequencing and array-based technologies and Next Generation Genomic Co., Ltd. (NGG Thailand), the Association of Southeast Asian Nations (ASEAN) leaders in
GenSight Biologics to Host a Key Opinion Leader Webinar on the Nature Medicine Case Report: Visual Recovery after GS030 Optogenetic Treatment
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
QIAGEN stellt erstes von der FDA zugelassenes gewebebasiertes Begleitdiagnostikum zur Identifizierung von NSCLC-Patienten mit der KRAS-G12C-Mutation bereit und erweitert damit die Möglichkeiten der Präzisionsmedizin im Bereich Lungenkrebs
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass die Zulassung für das Begleitdiagnostikum therascreen® KRAS RGQ PCR Kit (therascreen KRAS Kit) erweitert wurde. Das
QIAGEN Launches First FDA-approved Tissue Companion Diagnostic to Identify the KRAS G12C Mutation in NSCLC Tumours and Expand Precision Medicine Options in Lung Cancer
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of an expanded scope of companion diagnostic (CDx) claims for the therascreen® KRAS RGQ PCR Kit (therascreen KRAS
Charles River Laboratories to Participate in June Investor Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at three upcoming investor conferences, including:
-
Jefferies Virtual Healthcare
Illumina To Webcast Upcoming Investor Conference
Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference:
-
Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021